Get the Stockscreener App
1.28
1.59%
0.02
After Hours:
1.28
NanoViricides Inc stock is traded at $1.28, with a volume of 238.73K.
It is up +1.59% in the last 24 hours and up +9.40% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.26
Open:
$1.25
24h Volume:
238.73K
Relative Volume:
0.55
Market Cap:
$32.68M
Revenue:
-
Net Income/Loss:
$-8.09M
P/E Ratio:
-2.9398
EPS:
-0.4354
Net Cash Flow:
$-7.37M
1W Performance:
-11.11%
1M Performance:
+9.40%
6M Performance:
+37.59%
1Y Performance:
-10.49%
1-Day Range:
$1.23
$1.295
1-Week Range:
$1.23
$1.56
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.28 | 36.76M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
NanoViricides files Phase II NV-387 Ebola trial in Congo - scanx.trade
NanoViricides Extends President Diwan Through June 2027 at $400,000 Salary - Minichart
NV3P Forecast — Price Target — Prediction for 2027 - TradingView
Book value per share of NanoViricides, Inc. – HAN:NV3P - TradingView
NanoViricides, Inc. Balance Sheet – HAN:NV3P - TradingView
NanoViricides, Inc. (NNVC) Files 10-K; NV-387 Enters Phase II Trials - TradingView
Nanoviricides Q4 Results: Loss narrows 23% YoY to $(0.10) per share - scanx.trade
NanoViricides wins DRC approval for Phase II Ebola trial - scanx.trade
NanoViricides: Fiscal Q4 Earnings Snapshot - kare11.com
NANOVIRICIDES, INC. FY 2026: Revenue $0 EPS ($0.41) — 10-K Summary - TradingView
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides - ACCESS Newswire
Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
NanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NanoViricides, Inc. (NNVC) Latest Stock News & HeadlinesYahoo Finance - Yahoo! Finance Canada
NanoViricides Inc. (NNVC) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides - ACCESS Newswire
$Nanoviricides (NNVC.US)$ that was fast lol - Moomoo
This drug will change the world. - Moomoo
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides - Yahoo Finance
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo - ACCESS Newswire
Cash flow from financing activities of NanoViricides, Inc. – HAM:NV3P - TradingView
Operating cash flow per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Return on equity % of NanoViricides, Inc. – HAM:NV3P - TradingView
Gross margin % of NanoViricides, Inc. – HAM:NV3P - tradingview.com
CapEx per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Total debt per share of NanoViricides, Inc. – HAM:NV3P - TradingView
NanoViricides (NNVC) Slips 3.7% to $1.04, Hovering Near Key SupportWedge Breakout - dars.gov.et
Basic earnings per share (basic EPS) of NanoViricides, Inc. – HAM:NV3P - TradingView
NanoViricides Registers Phase II Ebola Trial for Oral Antiviral NV-387 in DRC - citybuzz.co
News by ACCESS Newswire on TradingView, 2026-09-08 - TradingView
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - ACCESS Newswire
NanoViricides (AMEX: NNVC) May Generate Up to $4.4 Million Through Warrant Exercises - Kalkine Media
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for MeaslesEnables Priority Review Voucher - ACCESS Newswire
U.S. measles cases reach 2,903 by Aug. 27 as NanoViricides prepares a trial - Stock Titan
NanoViricides Inc. (NNVC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
NNVC Q2 2026 Earnings: Narrower-than-Expected Loss Highlights Clinical-Stage DisciplineAnalyst Consensus Shift - dars.gov.et
NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Pre-Revenue DevelopmentEarnings Analysis - dars.gov.et
NanoViricides Inc. (NNVC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
NanoViricides (NNVC) Q2 2026 Earnings: Profit Per Share Surpasses Its Benchmark in the Latest Session; Closing Reaction: The Stock Loses 4.51% for the Current SessionProfit Guidance Range - vinanet.vn
NanoViricides (NNVC) Chart: Ends Lower by 3.08% at $1.29 in the Latest Session; Technical View: the Supplied Trading Band Runs From $1.23 to $1.35 in the Available RecordFibonacci Fan - vinanet.vn
NanoViricides (NNVC) Results Breakdown: EPS Exceeds Its Estimate; After Earnings: Shares Move Higher 1.53% - dars.gov.et
NanoViricides (NNVC) Technicals: Ends Up by 1.53% at $1.33 in the Latest Reading; Immediate View: Support at $1.26 and Resistance at $1.40 Frame the Range in the Available RecordWyckoff Accumulation - vinanet.vn
NanoViricides (NYSE American: NNVC) sets up warrant resale, up to $4.4M cash - Stock Titan
NanoViricides (NNVC) Levels: Finishes 0.82% Down at $1.33 at the Close; Chart Watch: Traders Can Monitor the $1.26-$1.40 Range in the Current UpdateHigh Conviction Picks - vinanet.vn
NanoViricides Prepares for Phase II Ebola Trial of Oral Drug Candidate in DRC - citybuzz -
Ebola outbreak has killed 2,325 as oral drug trial nears - Stock Titan
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
ETFs Investing in NanoViricides, Inc. Stocks - TradingView
NNVC Q2 2026 Earnings: EPS Surprise of 22.97% Bolsters Sentiment as Shares Rise 1.47%Interim Report - vinanet.vn
NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Marks 22.97% Positive SurpriseQuarterly Earnings Report - vinanet.vn
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):